Welcome to our dedicated page for OmniAb SEC filings (Ticker: OABI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
OmniAb, Inc. filings document the public-company disclosures of an antibody discovery technology business that licenses its platform to pharmaceutical, biotechnology and academic partners. Its Form 8-K reports furnish operating and financial results, partner program updates, guidance-related disclosures and other material events tied to the company’s licensing, service, milestone and royalty model.
The company’s proxy and governance filings cover annual meeting matters, director elections, auditor ratification, shareholder voting results and bylaw amendments addressing proxy-solicitation procedures and stockholder proposal mechanics. OmniAb filings also identify its emerging growth company status, Nasdaq-listed common stock and warrants, and recurring capital-structure and governance disclosure topics.
Janus Henderson Group plc reports a small, passive holding in OmniAb, Inc.'s common stock, amounting to roughly 945,956 shares which the filing states represents 0.8% of the class. The disclosure shows the firm has shared voting and dispositive power over these shares (no sole voting or dispositive power reported), and the filing identifies indirect subsidiaries (JHIUS, JHIUKL and JHIAIFML) as registered investment advisers providing advice to managed portfolios.
The filing includes a certification that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. The filing also includes a power of attorney authorizing designated compliance officers to execute ownership reports on the company's behalf.
OmniAb, Inc. (OABI) Q2 2025 condensed summary. Total revenue was $3.897 million for the three months ended June 30, 2025 versus $7.614 million in Q2 2024. Net loss was $15.875 million in Q2 2025 versus $13.631 million in Q2 2024; six-month net loss was $34.075 million versus $32.592 million prior-year. Cash and cash equivalents declined to $18.281 million and short-term investments were $23.334 million as of June 30, 2025.
Operational and liquidity highlights: the filing reports 100 active partners and 381 active programs, including 28 OmniAb-derived antibodies in clinical development, one under regulatory review, and three approved partner products. Management states existing cash, cash equivalents and short-term investments are sufficient to support operations for at least the next 12 months. The company recognized a $3.0 million gain from sale of an ion channel asset in Q2 2025.
OmniAb, Inc. (OABI) – Form 4 filed 18-Jun-2025
Director Steven Love reported several equity transactions dated 17-Jun-2025. The filing shows a routine mix of RSU vesting, fresh equity grants and the associated increase in directly held common shares.
- RSU vesting (Code M): 20,000 previously awarded restricted stock units converted into an equal number of common shares. Mr. Love’s direct shareholdings rose to 58,333 shares following the conversion.
- New RSU grant (Code A): 20,000 RSUs were awarded. These units vest in full on the earlier of OmniAb’s next annual shareholder meeting or the first anniversary of the grant date.
- New stock option grant (Code A): 40,000 options with a strike price of $1.70 and a 10-year term (expiring 17-Jun-2035) were issued. The option vests in full on the same schedule as the RSUs.
Post-transaction derivative holdings now comprise 46,667 RSUs and 40,000 stock options, while non-derivative ownership stands at 58,333 common shares. No open-market sales were disclosed, indicating that all changes stem from equity compensation and not from dispositions that might pressure the share float.
Because the reported activities involve standard director compensation and do not reflect purchases or sales on the open market, the filing is generally viewed as neutral-to-slightly-positive: it aligns the director’s incentives with shareholders without signaling divestiture. Material financial performance data is not included in this filing.
OmniAb, Inc. (OABI) – Form 4 insider activity dated 06/17/2025
Director John L. Higgins reported multiple equity transactions. He converted 20,000 previously granted RSUs (transaction code M), receiving an equal number of common shares at no cash cost and lifting his directly held stake to 2,851,887 shares. No shares were sold.
On the same day, the board granted Higgins a new equity package comprising 20,000 RSUs and 40,000 stock options with a $1.70 exercise price expiring 06/17/2035. Both awards vest in full on the earlier of the next annual shareholder meeting or 12 months from grant, aligning with the company’s typical director compensation schedule.
Post-transactions, Higgins’ derivative exposure consists of 33,172 unvested RSUs and 40,000 unexercised options. The filing signals continued long-term alignment as the insider’s net ownership increased and no dispositions were made. The incremental dilution from the new awards is de minimis relative to OmniAb’s outstanding share count and does not alter the firm’s capital structure.
Form 4 filing for OmniAb, Inc. (OABI) dated 18-Jun-2025 discloses equity transactions by director Carolyn R. Bertozzi on 17-Jun-2025.
- Common stock: 20,000 shares were acquired upon vesting of previously granted restricted stock units (RSUs). Post-transaction direct ownership stands at 75,539 shares.
- New equity grants: (i) 20,000 RSUs, each convertible into one common share, and (ii) a stock option for 40,000 shares with a $1.70 exercise price and 17-Jun-2035 expiration. All new awards vest in full on the earlier of the next annual shareholder meeting or the first anniversary of the 17-Jun-2025 grant date.
- No dispositions of shares occurred; all reported transactions increase or maintain the insider’s exposure to OmniAb’s equity.
These routine director equity awards and vesting events align incentives with shareholders and do not, by themselves, alter OmniAb’s fundamentals. The filing satisfies Section 16 reporting obligations and contains no indications of sales, pledges, or derivative hedging.